Evidence map›Paper›PMID 35365934›Full record

ArticleCancer science2022

Glycoprotein NMB promotes tumor formation and malignant progression of laryngeal squamous cell carcinoma.

Lev Manevich, Yukari Okita, Yasuhito Okano, Takehito Sugasawa, Kunio Kawanishi, Thanasis Poullikkas, Linda T L Dang Cao, Ling Zheng, Masahiro Nakayama, Shin Matsumoto and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Tumor-expressed GPNMB orchestrates Siglec-9Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Lev ManevichExperimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Yukari OkitaExperimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0002-7279-4634
Yasuhito OkanoExperimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Takehito SugasawaLaboratory of Sports Medicine, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Kunio KawanishiExperimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Thanasis PoullikkasExperimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Linda T L Dang CaoExperimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Ling ZhengExperimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Masahiro NakayamaOtolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0001-9285-7877
Shin MatsumotoOtolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Keiji TabuchiOtolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Mitsuyasu KatoExperimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0001-9905-2473
University of Tsukuba · JP

Funding

Japan Society for the Promotion of Science JP18H02676Japan Society for the Promotion of Science JP19K07658Japan Society for the Promotion of Science JP19K17730Japan Society for the Promotion of Science JP20K20597
6 · The paper itself

Abstract

Laryngeal squamous cell carcinoma (LSCC), although one of the most common head and neck cancers, has a static or slightly decreased survival rate because of difficulties in early diagnosis, lack of effective molecular targeting therapy, and severe dysfunction after radical surgical treatments. Therefore, a novel therapeutic target is crucial to increase treatment efficacy and survival rates in these patients. Glycoprotein NMB (GPNMB), whose role in LSCC remains elusive, is a type 1 transmembrane protein involved in malignant progression of various cancers, and its high expression is thought to be a poor prognostic factor. In this study, we showed that GPNMB expression levels in LSCC samples are significantly higher than those in normal tissues, and GPNMB expression is observed mostly in growth-arrested cancer cells. Furthermore, knockdown of GPNMB reduces monolayer cellular proliferation, cellular migration, and tumorigenic growth, while GPNMB protein displays an inverse relationship with Ki-67 levels. Therefore, we conclude that GPNMB may be an attractive target for future LSCC therapy.

Indexed as

Head and Neck NeoplasmsLaryngeal NeoplasmsMicroRNAsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGlycoproteinsHumansMembrane GlycoproteinsPromoter Regions, GeneticSquamous Cell Carcinoma of Head and NeckTranscription FactorsGlycoproteinsGPNMB protein, humanMembrane GlycoproteinsMicroRNAsTranscription Factorscell migrationdormancyglycoprotein NMBlaryngeal squamous cell carcinomatumorigenesis

Identifiers

PMID35365934
PMCPMC9459245
OpenAlexW4223893846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.